We’ve all been there. Knee-deep in a six-day bro split, halfway through your fourth set of lunges, wondering why you’re dedicating an entire session to a single muscle group. The DOMS are relentless, ...
GSK acquires exclusive rights to Syndivia's ADC for mCRPC, enhancing its oncology pipeline with advanced GeminiMab technology. The agreement, valued at $357 million, includes upfront, success-based, ...
Please provide your email address to receive an email when new articles are posted on . A novel assay may help direct antibody-drug conjugate therapy through measurements of HER2 and TROP2. Most ...
Adagene to provide proprietary antibody to ConjugateBio for development as novel bispecific ADCs SAN DIEGO and SUZHOU, China and PRINCETON, N.J., July 08, 2025 (GLOBE NEWSWIRE) -- Adagene Inc.
Vaxcyte Inc. (NASDAQ:PCVX) on Monday released topline results from its Phase 2 dose-finding study evaluating the safety, tolerability and immunogenicity of VAX-24, a 24-valent pneumococcal conjugate ...
ABBV-154, an antibody-drug conjugate comprising adalimumab conjugated to a proprietary glucocorticoid receptor modulator, shows potential for extending flare-free periods in patients with ...
MARSEILLE, France--(BUSINESS WIRE)--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) will host an event for institutional investors and analysts ...
These recommendations have been adopted by the CDC Director and are now official. The US Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) has ...
RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that the U.S. Centers for Disease Control and Prevention’s (CDC’s) Advisory ...
Riding high on its Daiichi Sankyo-partnered antibody drug conjugate (ADC) Enhertu—and banking on an approval for its next ADC contender datopotamab deruxtecan this winter—AstraZeneca is placing a big ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results